August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion of an $11 million Series A financing for its recombinant adeno-associated virus (AAV)-based gene therapy for dilated cardiomyopathy (DCM). The gene therapy is indicated for patients with DCM due to mutations in the BAG3 gene.
